Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1996, for The Female Health Company (also referred to as VERU INC. in metadata). The Company is a startup, boutique entity focused on women's health, specifically the commercialization of the female condom (sold as "Reality" in the U.S. and "Femidom"/"Femy" internationally). The reporting period reflects significant structural changes, including the sale of its former "Holdings" segment (discontinued operations) in January 1996 and the acquisition of Chartex Resources Limited (manufacturing and international rights) on February 1, 1996.
Key Financial Metrics
| Metric | Three Months Ended June 30, 1996 | Nine Months Ended June 30, 1996 | Balance Sheet (June 30, 1996) |
|---|---|---|---|
| Net Revenues | $723,560 | $1,454,068 | N/A |
| Gross Profit (Loss) | $(200,726) | $(667,673) | N/A |
| Operating Loss | $(1,808,254) | $(4,158,065) | N/A |
| Net Loss | $(1,903,289) | $(4,347,242) | N/A |
| Cash and Equivalents | N/A | N/A | $429,043 |
| Total Current Liabilities | N/A | N/A | $6,276,755 |
| Stockholders' Equity | N/A | N/A | $3,596,384 |
Unit Sales: 857,000 units sold in the three months ended June 30, 1996 (63% increase vs. prior year). Total worldwide sales for the nine months were 1,607,000 units.
Debt: Includes $2,160,000 in notes payable to stockholders and a $1.6 million mortgage on the Chartex facility due in October 1996.
Material Changes vs. Prior Period
- Revenue: Quarterly revenue increased 21% to $723,560, driven by the Chartex acquisition and a 63% increase in unit sales. However, nine-month revenue decreased 8% to $1,454,068 due to reduced marketing spend in early 1996 and lower average selling prices in the U.S. public sector.
- Gross Margin: The Company shifted from a gross profit of $161,838 in the prior year quarter to a gross loss of $(200,726). This is primarily attributed to fixed manufacturing overheads at the newly acquired Chartex facility and a $300,000 inventory obsolescence reserve.
- Expenses: General and administrative expenses surged 254% in the quarter (to $642,230) and 100% for the nine months (to $1,573,148) due to the consolidation of Chartex. Conversely, "Reality exclusivity fees" dropped to zero as the Company acquired the rights previously licensed from Chartex.
- Discontinued Operations: The Company sold its "Holdings" segment in January 1996, resulting in a nominal loss of $4,461 on the sale. Prior year results included significant income from this segment.
Outlook, Risks, and Management Commentary
Liquidity and Capital Needs: Management states that current sales do not generate sufficient revenue to fund operations. The Company estimates a cash break-even volume of 18.8 million units annually. It expects to continue reporting operating losses until at least the third quarter of fiscal 1997. Significant additional working capital is required.
Financing Activities:
- Commenced a public stock offering in June 1996, raising approximately $2.8 million net (700,000 shares sold).
- Received $310,000 of a $744,000 U.K. economic development grant (remainder contingent on performance).
- Secured $2,160,000 in bridge financing from stockholders.
Risks and Contingencies:
- Capital Shortfall: If the Company cannot source additional funds, it may be forced to sell assets or cease operations.
- Debt Maturities: Significant debt obligations mature in late 1996 and early 1997, including the Chartex mortgage ($1.6M) and shareholder notes ($2.16M).
- Contingent Liabilities: The Company remains contingently liable for approximately $4.5 million in obligations (leases and employment agreements) related to the sold "Holdings" segment if the buyer fails to pay.
- Inventory Risk: High inventory levels ($2.2M net) carry a risk of further writedowns if sales do not accelerate.
Strategy: Focus on expanding distribution in Asian markets (Korea, Japan, China) and increasing sales to global public sector organizations (WHO, UNAIDS) to cover fixed manufacturing costs.
Investor Verification Checklist
- Cash Runway: Verify if the $2.8M raised in the recent offering and the $429k cash on hand are sufficient to cover the $6.3M in current liabilities and operating losses through Q3 1997.
- Debt Refinancing: Confirm the status of the $1.6M Chartex mortgage due in October 1996 and the $2.16M shareholder notes.
- Inventory Valuation: Assess the adequacy of the $1.3M inventory reserve given the slow sales velocity and potential for expiration.
- Contingent Liabilities: Review the terms of the "Holdings" sale to understand the likelihood of the Company having to pay the $4.5M in assumed liabilities.
- Break-even Feasibility: Evaluate the realism of the 18.8 million unit annual sales target required to reach cash break-even.